IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025
On February 27, 2025, Imunon, Inc. (IMNN) announced financial results for 2024 and provided a business update. The company is currently finishing...
478 Views
IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25
Imunon, Inc. (IMNN) is finishing preparations to initiate a Phase 3 clinical trial of its lead development compound, IMNN-001, in the treatment of...
297 Views
IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001
On November 25, 2024, Imunon, Inc. (IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) on its proposed plan...
349 Views
IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer Trial
On November 7, 2024, Imunon, Inc. (IMNN) announced financial results for the third quarter of 2024 and provided a business update. Following...
175 Views
IMNN: Positive Results for OVATION 2 Trial Supports Advancing IMNN-001 Into Phase 3 Study
On July 30, 2024, Imunon, Inc. (IMNN) announced positive topline results for the Phase 2 OVATION 2 Trial of IMNN-001 in patients with advanced...
298 Views